Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALRN-6924 in advanced solid tumors or lymphomas with wild-type p53
NCT02264613Phase 2Completed
- Sponsor
- Rein Therapeutics
- Start
- Oct 2014
- Primary completion
- Mar 2020
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sulanemadlin in solid tumor, lymphoma, peripheral T-cell lymphoma (PTCL), sponsored by Rein Therapeutics. Started Oct 2014; status: completed.
02
Drugs
sulanemadlin
03
Conditions
solid tumorlymphomaperipheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT02264613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02264613.